Sorafenib plus valproic acid for infant spinal glioblastoma

Area of Science:

• Pediatric Oncology
• Neuro-oncology
• Molecular Targeted Therapy

Background:

• Spinal glioblastoma multiforme (GBM) is a rare and aggressive pediatric central nervous system tumor.
• Current treatment options for pediatric spinal GBM often yield poor prognoses, necessitating novel therapeutic strategies.

Observation:

• The study presents a case of an infant diagnosed with spinal GBM.
• The infant's condition deteriorated despite conventional treatments including radiotherapy and chemotherapy.

Findings:

• Immunohistochemical analysis revealed activation of the Raf-MEK-ERK signaling pathway in the tumor sample.
• Targeted therapy with sorafenib (a Raf inhibitor) and valproic acid resulted in significant tumor size reduction and clinical symptom improvement.

Implications:

• Targeted inhibition of the mitogen-activated protein kinase pathway may represent a viable therapeutic approach for pediatric spinal GBM.
• The combination of sorafenib and valproic acid warrants further clinical investigation for managing childhood GBM.